Search Results
Jun 01, 2026, 07:00 ET Biond Biologics and Guangzhou-Israel Biotechnology Fund ("GIBF") Announce Closing of $8 Million Investment and Collaboration
targeting the ILT2–HLA-G axis. BND-22 has demonstrated efficacy in heavily treated cancer patients in indications that hardly respond to Immuno-Oncology (IO) therapies, such as MSS-CRC, and is currently being evaluated in an ongoing Phase 2 study at MD Anderson Cancer Center.BND-67 is Biond's next-generation
More news about: Biond Biologics Ltd.; GIBF
May 31, 2026, 20:15 ET ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
an ORR of 66.7% and a DCR of 100.0%. In the 30 mg/kg monotherapy cohort, patients whose disease had progressed following prior immunotherapy (IO) plus platinum-based chemotherapy —— a setting with significant unmet medical need—achieved an ORR of 30.8% and a DCR of 84.6%."Cold
More news about: CStone Pharmaceuticals
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC IBI363 has entered a global Phase 3 clinical study (MarsLight-11) for IO-resistant squamous NSCLC; pending regulatory communications, initiation of a global Phase 3 clinical study of IBI363 for IO-resistant non-squamous
More news about: Innovent Biologics
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
dose optimization of IBI363 is precisely tailored to patient immune status and TME features across different treatment lines.For patients with IO-resistant NSCLC, these patients exhibit an immunosuppressive tumor microenvironment (TME) characterized by Treg enrichment, M2‑like tumor‑associated
More news about: Innovent Biologics
May 30, 2026, 20:00 ET 榮登《柳葉刀》主刊！蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗一線治療 PD-L1 陽性 NSCLC III期重磅結果發表
HR值分別為0.28和0.44；同時已觀察到總生存期(OS)的積極獲益趨勢，HR為0.55。蘆康沙妥珠單抗(sac-TMT)聯合組整體安全性可控，聯合治療與蘆康沙妥珠單抗(sac-TMT)單藥或帕博利珠單抗單藥已建立的安全性特征一致，未發現新的安全性信號。這是首個ADC聯合免疫檢查點抑制劑在NSCLC一線治療中達到主要終點的III期臨床研究，首次證明了「ADC+IO」方案(sac-TMT聯合帕博利珠單抗)作為NSCLC一線治療具有實現生存獲益的潛力。該成果問鼎《柳葉刀》主刊，表明這一療法的臨床價值與學術價值已獲得國際權威認可。關於蘆康沙妥珠單抗(sac-TMT)(佳泰萊®)作為公司的核心產品，蘆康沙妥珠單抗(sac-TMT)是一款公司擁有自主知識產權的新型TROP2
More news about: 科倫博泰
May 30, 2026, 20:00 ET Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
combined with an immune checkpoint inhibitor to meet its primary endpoint in the first line treatment of NSCLC, and for the first time demonstrate that "ADC+IO" combination of sac-TMT plus pembrolizumab has the potential to achieve survival benefit as first‑line therapy for NSCLC. The publication of these
More news about: Kelun-Biotech
May 30, 2026, 00:30 ET 2026 ASCO | 蘆康沙妥珠單抗(sac-TMT) III期OptiTROP-Lung05研究成果於ASCO口頭報告和《柳葉刀》同步發佈
全國牽頭主要研究者、同濟大學附屬東方醫院周彩存教授表示：「OptiTROP-Lung05研究取得的積極結果令人振奮。不僅為蘆康沙妥珠單抗在肺癌治療中的『應用前移』提供了循證證據，更率先驗證了『ADC+IO』協同策略在PD-L1陽性晚期NSCLC一線治療中的可行性，有望為廣大肺癌患者帶來全新的生存希望。」
More news about: 科倫博泰
May 29, 2026, 23:32 ET The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
encouraging. The study not only supports the application of sac‑TMT in an earlier-line setting for lung cancer, but also provides evidence of the 'ADC+IO' synergistic strategy being evaluated in the first-line setting for PD‑L1‑positive advanced NSCLC, potentially bringing a new option to a broad population
More news about: Kelun-Biotech
May 29, 2026, 06:00 ET iyO Secures Backing of Leading Litigation Funder for Intellectual Property Theft Case Against OpenAI
litigation funder Omni Bridgeway (ASX: OBL) in its federal trademark and trade secret litigation against OpenAI, Sam Altman, Jony Ive, and io Products Inc., along with former io co-founder Tang Yew Tan. Omni Bridgeway's financial backing ensures that iyO will be able to pursue this case on equal footing against
More news about: iyO, Inc.
May 28, 2026, 19:26 ET Phanes Therapeutics Announces Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting
Phase 3 trial in patients with 1L mPDAC.Spevatamig is an innate immunity enhancer (I2E), an emerging class of immuno-oncology (IO) agents. Unlike immune checkpoint inhibitors (ICIs) (also known as anti-PD1/anti-PD-L1 drugs) which activate T cells to kill cancer cells, I2Es
More news about: Phanes Therapeutics, Inc.
May 28, 2026, 12:23 ET Speaker Welch to Host 4th Annual Pride Month Celebration "Equality & Pride 365" on June 12th
addition to being hosted by Victoria Le Paige, this event will feature performances by many legendary entertainers from the Baton Show Lounge. With the IO Godfrey Rooftop Lounge offering incredible city views, this fundraiser has become one of the best political events of the summer.Tickets and sponsorships
More news about: The People for Emanuel Chris Welch
May 28, 2026, 08:00 ET DeepIntent Partners with Lane4.io to Launch a New Programmatic Path to Point-of-Care Inventory
multimedia:https://www.prnewswire.com/news-releases/deepintent-partners-with-lane4io-to-launch-a-new-programmatic-path-to-point-of-care-inventory-302783928.htmlSOURCE
More news about: DeepIntent
May 28, 2026, 02:06 ET Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC
activation via the X-body platform and highlight Opamtistomig's differentiated clinical advantages in first-line NSCLC.Opamtistomig's potential as an IO 2.0 pan-tumor backbone therapy is being validated in three key dimensions—broad antitumor activity, long-term survival benefit trends, and a safety profile
More news about: Nanjing Leads Biolabs Co., Ltd.
May 27, 2026, 08:00 ET Faster AI Inference enabled by 1000x Higher Scale with Delos Data™ Nonstop AI™
AI™ approachLarge ecosystem: Built within today's GPU and accelerator ecosystemsHigher scale: Delos Server brings scale-up IO to faceplace, enabling larger scale-up domainsBetter Visibility: Delos Mosaic™ software allows for fine-grained visibility into scale-up
More news about: Delos Data
May 26, 2026, 00:00 ET 輕薄筆電與多裝置辦工協作帶動 I/O 需求成長 Belkin 持續擴展其連接技術領導地位
View original content to download multimedia:https://www.prnewswire.com/apac/zh/news-releases/-io--belkin--302781176.htmlSOURCE Belkin
More news about: Belkin
May 22, 2026, 00:58 ET 2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable Safety
effector T cells rapidly, enhance T cell infiltration, and form an IO-sensitive immune microenvironment. Subsequently, a 1.5 mg/kg every three weeks (Q3W) regimen is adopted for the maintenance treatment, which could maintain the IO-sensitive tumor microenvironment, prolong the possible treatment cycles,
More news about: Innovent Biologics
May 21, 2026, 19:49 ET 2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
a global Phase 3 clinical study (MarsLight-11) for IO-resistant squamous NSCLC, the clinical trial design of which will also be presented at this ASCO. Pending regulatory communications, initiation of a global Phase 3 clinical study of IBI363 for IO-resistant non-squamous NSCLC is also planned.Updated
More news about: Innovent Biologics
May 21, 2026, 07:42 ET NuxGame Partners With 155.io to Bring Mobile-First Games to iGaming Operators
add-on.For more information, visit: https://nuxgame.com/blog/nuxgame-155io-partnershipAbout NuxGameNuxGame is an award-winning iGaming platform provider offering a complete ecosystem for online
More news about: NuxGame
May 20, 2026, 13:30 ET SITC Announces Keynote Speakers Dr. Ton Schumacher and Dr. Catherine J. Wu at its 41st Annual Meeting
once again bringing together the entire immuno-oncology (IO) ecosystem to present the most cutting-edge research at its Annual Meeting." remarked Ryan J. Sullivan, MD and 2026 Annual Program Committee Chair. "The meeting will explore the latest IO research including the opportunities with AI, personalized
More news about: Society for Immunotherapy of Cancer (SITC)
May 19, 2026, 08:00 ET Roland DG Signals Strategic Expansion into Industrial Digital Printing with New Portfolio Preview
critical. Together, the IO-300, RC-300 Series, and Hard UV Ink form a practical pathway for customers looking to modernize decoration processes without compromising durability expectations.VersaObject IO-300: Bridging Analog and Digital WorkflowsThe VersaObject IO-300 is a B2-size
More news about: Roland DGA
May 18, 2026, 11:34 ET AMI Announces a Shift-Left Initiative to De-Risk SoC Development for Arm Total Design in Collaboration with Arm and Synopsys
several steps beyond that of verification with the Arm Fixed Virtual Platform (FVP), adding runtime silicon components, such as Synopsys high-speed IO, security, and Silicon Lifecycle Management (SLM) IP. Design teams can significantly reduce deployment time for the silicon and platforms through this
More news about: AMI
May 14, 2026, 09:01 ET Movate Partners with Beacon Mobility to Drive AI-Led Cloud and Cybersecurity Transformation
agents, it brings together human expertise and technology to help organizations rethink operating models for efficiency and growth. Powered by Mova iO, its intelligent outcomes platform, Movate delivers practical, scalable, and industry-contextualized solutions that address real business challenges.For
More news about: Movate
May 14, 2026, 09:00 ET Movate Partners with Beacon Mobility to Drive AI-Led Cloud and Cybersecurity Transformation
agents, it brings together human expertise and technology to help organizations rethink operating models for efficiency and growth. Powered by Mova iO, its intelligent outcomes platform, Movate delivers practical, scalable, and industry-contextualized solutions that address real business challenges.For
More news about: Movate
May 12, 2026, 20:00 ET Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody
closely and leveraged complementary advantages with each other to efficiently drive the R&D of the collaborative product candidates. Based on our ADC+IO strategies, we will actively explore the potential of combining SKB118 with our proprietary ADC assets to unlock the synergistic value of our portfolio
More news about: Kelun-Biotech
May 12, 2026, 09:01 ET GrubMarket Announces the Spring 2026 Release of its AI-Powered Software Ecosystem
fully integrated technology platform spanning ERP, AI, and eCommerce. This release introduces significant enhancements across WholesaleWare, Orders IO, and AI Orders, delivering new capabilities designed to help restaurant and foodservice distributors and produce wholesalers improve efficiency, elevate
More news about: GrubMarket